Erichs M, Rothgardt N P, Andersson E
Postgrad Med J. 1980;56 Suppl 2:53-6.
The effect of long-term treatment with labetalol was evaluated in an open clinical investigation in a total of 32 patients (15 women, 17 men), mean age 56 years (range 18-81 years). Labetalol was used in a mean daily dose of 1356 mg (range 400-3000 mg) either as mono-therapy or in combination with other drugs. Twenty-three patients were treated for more than six months, with a mean period of treatment of forty months. Thirteen of these 23 patients continue on treatment with a mean period of treatment of fifty-one months (range 6-65 months). This study does not lend support to the idea of tolerance developing to the effects of labetalol. There were no signs of liver, kidney or bone marrow involvement, and there were no changes in the retina. In 13 of the 32 patients the treatment was discontinued following subjective complaints possibly induced by the drug, partly orthostatic hypotension, and partly side effects probably related to the beta- adrenoceptor blocking effect of labetalol. Until the incidence of subjective side effects has been carefully evaluated labetalol will be used with reservations, especially as a first choice in the treatment of hypertension.
在一项开放性临床研究中，对总共32例患者（15名女性，17名男性）进行了拉贝洛尔长期治疗效果的评估，患者平均年龄56岁（范围18 - 81岁）。拉贝洛尔的平均日剂量为1356毫克（范围400 - 3000毫克），可作为单一疗法或与其他药物联合使用。23例患者接受治疗超过6个月，平均治疗时间为40个月。这23例患者中有13例继续接受治疗，平均治疗时间为51个月（范围6 - 65个月）。本研究不支持对拉贝洛尔的效应产生耐受性这一观点。没有肝脏、肾脏或骨髓受累的迹象，视网膜也没有变化。32例患者中有13例因可能由药物引起的主观不适而停药，部分是体位性低血压，部分是可能与拉贝洛尔的β - 肾上腺素能受体阻断作用相关的副作用。在对主观副作用的发生率进行仔细评估之前，拉贝洛尔的使用将有所保留，尤其是作为高血压治疗的首选药物时。
